摘要
目的:比较阿立哌唑与利培酮治疗精神分裂症的疗效及安全性。方法:对符合CCMD-3关于精神分裂症诊断标准的77例首发精神分裂症患者,根据随机对照方案分别使用阿立哌唑和利培酮治疗,疗程共8周。采用阳性症状与阴性症状量表(PANSS)进行疗效评定,采用不良反应量表(TESS)进行不良反应评定。结果:治疗8周后,阿立哌唑组显效率为71.8%,有效率为89.7%;利培酮组显效率为71.1%,有效率为86.8%。两种药物疗效差异无显著性(x2=0.16,P>0.05)。PANSS量表各因子减分率两组治疗前和治疗后第2、4、8周比较有显著性差异(P<0.01),说明两药均有较好的疗效。最终PANSS量表减分率总分,两组间无显著性差异(t=0.44,P>0.05),说明两药疗效相当。阿立哌唑组总的不良反应发生率为38.4%,利培酮组为68.4%,两组间差异有显著性(x2=6.89,P<0.01)。阿立哌唑组出现较多的不良反应是恶心厌食;利培酮组以体重增加、月经紊乱和泌乳较多。结论:两种药物对治疗精神分裂症的阳性、阴性症状及精神病理均有确切的疗效,且安全性相对高。
Objective：To compare the efficacy and safety of aripiprazole and risperidone in the treatment of schizophrenia. Methods：Seventy- seven patients with schizophrenia by CCMD- 3 are randomly allocated to two groups treated with aripiprazole or risperidone respectively for 8 weeks. The Positive and Negative Syndrome Scale （ PANS - S） and Treatment Emergent Side effect Scale （TESS） were used to e -valuate the efficacy and adverse effect respectively. Results： The efficacy rate of aripiprazole was 89.7% ,in which 71.8% were improved markedly. The efficacy rate of risperdone was 86.8% ,in which 71.1% were improved markedly. The PANSS scores in both groups no significantly after treatment for eight weeks （ P 〉 0.05 ）. The incidence of untoward reaction in aripiprazole group was lower than that in ris - perdone group and the difference was significant （ P 〈 0.05 ）. Conclusions ： Both drugs are effective exactly in the treatment of schizophrenic patients and have fewer side effects.
出处
《中国民康医学》
2007年第5期181-182,共2页
Medical Journal of Chinese People’s Health
